Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients.

Ajalaya TeyateetiArmeen MahvashJames P LongMohamed E AbdelsalamRony AvritscherBeth ChasenAhmed O KasebJoshua D KubanRavi MurthyBruno C OdisioAchiraya TeyateetiHomer A MacapinlacSrinivasan Cheenu Kappadath

Published in: Journal of hepatocellular carcinoma (2020)

TARE_alone provided the most prominent survival benefit in IHT ≤50%-without ADF patients who had unilobar HCC and serum AFP <400 ng/mL. TARE and sorafenib yielded the best outcomes in patients with IHT ≤50% and serum AFP <400 ng/mL, with some additional grade 1-2 AEs compared to TARE only.

Keyphrases

end stage renal disease
liver metastases
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
squamous cell carcinoma
metabolic syndrome
skeletal muscle
radiation therapy